comprehensive -WSS

comprehensive

author：fashion 2025-08-19 20:45:01 - browse：36835

Jamy Ard (left) and Robert Lustig (right) on the 2023 STAT Breakthrough Summit stage -- coverage from STAT — Obesity experts Jamy Ard (left) and Robert Lustig speak at a panel during the 2023 STAT Breakthrough Summit. Sarah Gonzalez for STAT

Amid rising demand for drugs like Wegovy, Ozempic, and Mounjaro that can lead to significant weight loss, some obesity experts are concerned about the drugs’ costs — both to patients’ finances and to their health.

Speaking at a panel on new obesity treatments at the STAT Breakthrough Summit in San Francisco on Thursday, one expert cited a large clinical trial for Wegovy that showed that about 40% of the weight participants lost was lean mass. Side effects like nausea, vomiting, and a possible link to rare cases of pancreatitis also still plague this newest class of drugs, which imitate the effects of a hormone called glucagon-like peptide 1 (GLP) that helps people feel full.

“That’s what starvation does. You lose equal amounts of muscle and fat,” said Robert Lustig, emeritus professor of pediatrics at the University of California, San Francisco. “If you’re a person 60 years old or over and you’re losing muscle, your risk of dying just went up exponentially. So we may be … robbing Peter to pay Paul.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Researchers use wearables data and AI to predict preterm birth risk

WSS

Address the ethical violations that led to 'Three Identical Strangers'

After a drawn out lobbying fight, ARPA

New definition of a human embryo proposed amid rapid advances

Listen: Who gets the credit for GLP

Trump's false claims about Georgia's 2020 election long debunked

Menendez indictment could see pharma lose a key ally

knowledge

comprehensive

knowledge

In age of alternative facts, a scholarly course on calling out crap

ProMED sees offers of support, but its future remains unclear

Medicare details structure of new drug price negotiation program

FDA advisers vote against ALS treatment from BrainStorm

How one medical school became remarkably diverse

Cigna to pay $172 million to settle Medicare Advantage fraud probe

Hollywood unions extend contract negotiations for actors

Did you have Obamacare on your GOP debate bingo card?

The high cost of giving birth even with insurance

FDA seeks to regulate lab

focus

Mindstrong's demise and the future of mental health care

Clinical trials must include more disabled people

Menendez indictment could see pharma lose a key ally

Trump's false claims about Georgia's 2020 election long debunked

Listen: Who gets the credit for GLP

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

focus

leisure time

hotspot

Wikipedia